On July 20, Hengrui Pharma rose 3.36% in regular trading, trading at 56.75 HKD/share, with turnover of approximately 42.16 million HKD.

On the news front, the company disclosed on July 19 its latest share buyback progress, having cumulatively repurchased 13.75 million A-shares through the Shanghai Stock Exchange's centralized bidding system, with total consideration of RMB 853 million. The buyback price ranged from RMB 45.30 to RMB 70.00 per share, representing approximately 0.21% of total share capital. In July alone, the company repurchased 280,000 shares at prices between RMB 53.75 and RMB 54.05, spending RMB 15 million. The continued buyback signals management confidence in the company's long-term value.

Additionally, China Guoxin announced on the evening of July 19 that it has deployed over RMB 50 billion through a dedicated stock buyback and stake-increase re-lending facility to maintain market stability, boosting overall sentiment. The pharmaceutical sector rallied broadly, with CSPC Pharma up 4.2%, Sunshine Pharma up 3.57%, and Asymchem up 3.33%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)